Merck Serono targets €300m savings
This article was originally published in Scrip
Merck KGaA is aiming to achieve net cost savings of €300 million by 2014, for total one-off costs of €600 million. The company said that eliminating the Geneva headquarters and R&D hub of its largest division, Merck Serono, would provide a large proportion of those savings, but reiterated that its efficiency plan would affect all divisions in all regions.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.